WASHINGTON — The Biotechnology Innovation Organization on Monday announced a significant restructuring accompanied by a shakeup.
BIO is conducting layoffs that will total around 30 people, according to an email announcement obtained by STAT. In the email, BIO CEO John Crowley said the changes are intended to “better align our operations with our mission and the strategic priorities.”
In the last year, drugmakers have talked up the prospect of medicines discovered or designed by artificial intelligence. AI could accelerate the pace of new
Certain antibiotics for treating neutropenic fever and infections following allogeneic hematopoietic cell transplantation (allo-HCT) were associated with a higher risk for acute graft-versus-host disease (GvHD)
Scientists from the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory have discovered that a protein responsible for the synthesis of a key plant material
